The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine
Open accessAbstract
BACKGROUND: A novel translational pharmacology investigation was conducted by combining an in vitro efficacy target with mucosal tissue pharmacokinetic (PK) data and mathematical modeling to determine the number of doses required for effective human immunodeficiency virus (HIV) preexposure prophylaxis (PrEP). METHODS: A PK/pharmacodynamic (PD) model was developed by measuring mucosal tissue concentrations of tenofovir, emtricitabine, their active metabolites (tenofovir diphosphate [TFVdp] and emtricitabine triphosphate [FTCtp], respectively), and competing endogenous nucleotides (dATP and dCTP) in 47 healthy women. TZM-bl and CD4(+) T cells were used to identify 90% effective concentration (EC90) ratios of TFVdp to dATP and FTCtp to dCTP (alone and in combination) for protection against HIV. Monte-Carlo simulations were then performed to identify minimally effective dosing strategies to protect lower female genital tract and colorectal tissues. RESULTS: The colorectal TFVdp concentration was 10 times higher than that in the lower female genital tract, whereas concentrations of endogenous nucleotides were 7-11 times lower. Our model predicted that ≥98% of the population achieved protective mucosal tissue exposure by the third daily dose of tenofovir disoproxil fumarate plus emtricitabine. However, a minimum adherence to 6 of 7 doses/week (85%) was required to protect lower female genital tract tissue from HIV, while adherence to 2 of 7 doses/week (28%) was required to protect colorectal tissue. CONCLUSIONS: This model is predictive of recent PrEP trial results in which 2-3 doses/week was 75%-90% effective in men but ineffective in women. These data provide a novel approach for future PrEP investigations that can optimize clinical trial dosing strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096 · cited 2×
“Partners PrEP demonstrated 75% efficacy among heterosexual serodiscordant couples [1], and iPrEx demonstrated 44% efficacy among men who have sex with men (MSM) and transgender women [2].”
BackgroundAntiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., Tappero, J. W., Bukusi, E. A., Cohen, C. R., Katabira, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108524 · Cited by 3,256 · cited 2×
“Partners PrEP demonstrated 75% efficacy among heterosexual serodiscordant couples [1], and iPrEx demonstrated 44% efficacy among men who have sex with men (MSM) and transgender women [2].”
BackgroundAntiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., Henderson, F. L., Pathak, S. R., Soud, F. A., Chillag, K. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110711 · Cited by 1,996
Preexposure Prophylaxis for HIV Infection among African Women
Van Damme, L., Corneli, A., Ahmed, K., Agot, K., Lombaard, J., Kapiga, S., Malahleha, M., Owino, F., Manongi, R., Onyango, J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202614 · Cited by 1,603
Self-citationWei, X., Decker, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J. M., Saag, M. S., Wu, X., Shaw, G. M., & Kappes, J. C. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1896-1905.2002 · Cited by 1,569
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Marrazzo, J. M., Ramjee, G., Richardson, B. A., Gomez, K., Mgodi, N., Nair, G., Palanee, T., Nakabiito, C., van der Straten, A., Noguchi, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402269 · Cited by 1,296 · cited 2×
“Phase 3 clinical trials evaluating daily oral TDF, with or without FTC, for HIV PrEP have demonstrated mixed results in heterosexual women [1, 3, 4, 19].”
BackgroundConnor, R. I., Chen, B. K., Choe, S., & Landau, N. R. (1995) · Virology · doi:10.1006/viro.1995.1016 · Cited by 1,253
Platt, E. J., Wehrly, K., Kuhmann, S. E., Chesebro, B., & Kabat, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.4.2855-2864.1998 · Cited by 1,219
Grant, R. M., Anderson, P. L., McMahan, V., Liu, A., Amico, K. R., Mehrotra, M., Hosek, S., Mosquera, C., Casapia, M., Montoya, O., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70847-3 · Cited by 1,208
Anderson, P. L., Glidden, D. V., Liu, A., Buchbinder, S., Lama, J. R., Guanira, J. V., McMahan, V., Bushman, L. R., Casapía, M., Montoya-Herrera, O., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004006 · Cited by 1,020
Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature
Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975
He, J., Choe, S., Walker, R., Di Marzio, P., Morgan, D. O., & Landau, N. R. (1995) · Journal of Virology · doi:10.1128/jvi.69.11.6705-6711.1995 · Cited by 904
Baggaley, R. F., White, R. G., & Boily, M.-C. (2010) · International Journal of Epidemiology · doi:10.1093/ije/dyq057 · Cited by 713
Fletcher, C. V., Staskus, K., Wietgrefe, S. W., Rothenberger, M., Reilly, C., Chipman, J. G., Beilman, G. J., Khoruts, A., Thorkelson, A., Schmidt, T. E., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318249111 · Cited by 664
From Sewer to Saviour—Targeting the Lymphatic System to Promote Drug Exposure and Activity
Trevaskis, N. L., Kaminskas, L. M., & Porter, C. J. H. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4608 · Cited by 654
Kim, S. Y., Byrn, R., Groopman, J., & Baltimore, D. (1989) · Journal of Virology · doi:10.1128/jvi.63.9.3708-3713.1989 · Cited by 577
Donnell, D., Baeten, J. M., Bumpus, N. N., Brantley, J., Bangsberg, D. R., Haberer, J. E., Mujugira, A., Mugo, N., Ndase, P., Hendrix, C., et al. (2014) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000172 · Cited by 358
Patterson, K. B., Prince, H. A., Kraft, E., Jenkins, A. J., Shaheen, N. J., Rooney, J. F., Cohen, M. S., & Kashuba, A. D. M. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3003174 · Cited by 355
Self-citationAnimal models for HIV/AIDS research
Hatziioannou, T., & Evans, D. T. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2911 · Cited by 340
Intestinal lymphatic drug transport: an update
Porter, C. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00151-x · Cited by 337
Shaw, G. M., & Hunter, E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006965 · Cited by 326
Gao, W. Y., Shirasaka, T., Johns, D. G., Broder, S., & Mitsuya, H. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116463 · Cited by 231
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection
Anderson, P. L., Kiser, J. J., Gardner, E. M., Rower, J. E., Meditz, A., & Grant, R. M. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq447 · Cited by 192
Louissaint, N. A., Cao, Y.-J., Skipper, P. L., Liberman, R. G., Tannenbaum, S. R., Nimmagadda, S., Anderson, J., Everts, S., Bakshi, R. P., Fuchs, E. J., et al. (2013) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2013.0044 · Cited by 149
Margolis, D. M., Kewn, S., Coull, J. J., Ylisastigui, L., Turner, D., Wise, H., Hossain, M. M., Lanier, E. R., Shaw, L. M. J., & Back, D. J. (2002) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200209010-00006 · Cited by 83
Garcia-Lerma, J. G., Aung, W. S., Cong, M.-E., Zheng, Q., Youngpairoj, A. S., Mitchell, J. M., Holder, A. N., Martin, A. M., Kuklenyik, S., Luo, W., et al. (2011) · Journal of Virology · doi:10.1128/jvi.00311-11 · Cited by 75
Dose Response for Starting and Stopping HIV Preexposure Prophylaxis for Men Who Have Sex With Men
Seifert, S. M., Glidden, D. V., Meditz, A. L., Castillo‐Mancilla, J., Gardner, E. M., Predhomme, J. A., Rower, C., Klein, B., Kerr, B. J., Guida, L., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu916 · Cited by 66
Chakraborty, A., & Jusko, W. J. (2002) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.3000 · Cited by 57
Rollenhagen, C., Lathrop, M. J., Macura, S. L., Doncel, G. F., & Asin, S. (2014) · Mucosal Immunology · doi:10.1038/mi.2014.3 · Cited by 41
Yang, K.-H., Hendrix, C. W., Bumpus, N. N., Elliott, J. E., Tanner, K., Mauck, C. K., Cranston, R., McGowan, I., Richardson‐Harman, N., Anton, P. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106196 · Cited by 34
Self-citationEmmanuel, A. V., Kamm, M. A., & Beard, R. W. (2000) · Clinical Science · doi:10.1042/cs0980201 · Cited by 26
Holder, D., Hsuan, F. C., Dixit, R., & Soper, K. A. (1999) · Journal of Biopharmaceutical Statistics · doi:10.1081/bip-100101187 · Cited by 25
Reed, R. C., Dutta, S., & Liu, W. (2009) · Epilepsy Research · doi:10.1016/j.eplepsyres.2009.09.015 · Cited by 14
Cited by
Saag, M. S., Benson, C. A., Gandhi, R. T., Hoy, J. F., Landovitz, R. J., Mugavero, M. J., Sax, P. E., Smith, D. M., Thompson, M. A., Buchbinder, S. P., et al. (2018) · JAMA · doi:10.1001/jama.2018.8431 · Cited by 698
Günthard, H. F., Saag, M. S., Benson, C. A., del Rio, C., Eron, J. J., Gallant, J. E., Hoy, J. F., Mugavero, M. J., Sax, P. E., Thompson, M. A., et al. (2016) · JAMA · doi:10.1001/jama.2016.8900 · Cited by 656
Delany-Moretlwe, S., Hughes, J. P., Bock, P., Ouma, S. G., Hunidzarira, P., Kalonji, D., Kayange, N., Makhema, J., Mandima, P., Mathew, C., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00538-4 · Cited by 586
Molina, J.-M., Charreau, I., Spire, B., Cotte, L., Chas, J., Capitant, C., Tremblay, C., Rojas-Castro, D., Cua, E., Pasquet, A., et al. (2017) · The Lancet HIV · doi:10.1016/s2352-3018(17)30089-9 · Cited by 472
Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women
Klatt, N. R., Cheu, R., Birse, K., Zevin, A. S., Perner, M., Noël-Romas, L., Grobler, A., Westmacott, G., Xie, I. Y., Butler, J., et al. (2017) · Science · doi:10.1126/science.aai9383 · Cited by 428
Metadata
- Authors
- Cottrell, M. L., Yang, K. H., Prince, H. M. A., Sykes, C., White, N., Malone, S., Dellon, E. S., Madanick, R. D., Shaheen, N. J., Hudgens, M. G., Wulff, J., Patterson, K. B., Nelson, J. A. E., & Kashuba, A. D. M.
- Venue
- Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-02-24
- Volume
- 214
- Issue
- 1
- Pages
- 55-64
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2326890844
- Cited by
- 300
- References
- 33
- FWCI
- 34.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.